Literature DB >> 16806960

The development of platinum compounds and their possible combination.

Lara Maria Pasetto1, Mario Rosario D'Andrea, Alba Ariela Brandes, Elena Rossi, Silvio Monfardini.   

Abstract

Cisplatin plays a central role in cancer chemotherapy in spite of its toxicity. To circumvent this toxicity and to enhance its therapeutic index a lot of preclinical and clinical studies have been conducted and several thousand analogues have been synthesized. Much more analysis remains to be done, but nowadays, the absence of any definitive, biologically interpretable molecular predictor of activity is consistent with the idea that platinum compounds have multiple intracellular targets and that cells can have multiple mechanisms of resistance. This review analyses a part of these platinum compounds analyzed to date, their mechanism of action, resistance and the future trends in this sector.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806960     DOI: 10.1016/j.critrevonc.2006.02.003

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  18 in total

1.  Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling.

Authors:  Paola Gramatica; Ester Papa; Mara Luini; Elena Monti; Marzia B Gariboldi; Mauro Ravera; Elisabetta Gabano; Luca Gaviglio; Domenico Osella
Journal:  J Biol Inorg Chem       Date:  2010-06-06       Impact factor: 3.358

2.  Vibrational frequencies and intramolecular force constants for cisplatin: assessing the role of the platinum basis set and relativistic effects.

Authors:  Caroline A de Almeida; Larissa P N M Pinto; Hélio F Dos Santos; Diego F S Paschoal
Journal:  J Mol Model       Date:  2021-10-12       Impact factor: 1.810

3.  Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis.

Authors:  Xue-Jiao Lv; Li-Jing Zhao; Yu-Qiu Hao; Zhen-Zhong Su; Jun-Yao Li; Yan-Wei Du; Jie Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.

Authors:  Domingo A Román; Isabel Pizarro; Lidia Rivera; Carolina Torres; Juan Avila; Pedro Cortés; Marjorie Gill
Journal:  BMC Res Notes       Date:  2012-04-30

Review 5.  Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.

Authors:  Shigehira Saji
Journal:  BioDrugs       Date:  2013-10       Impact factor: 5.807

6.  Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.

Authors:  Victoria Hellberg; Inger Wallin; Sofi Eriksson; Emma Hernlund; Elin Jerremalm; Maria Berndtsson; Staffan Eksborg; Elias S J Arnér; Maria Shoshan; Hans Ehrsson; Göran Laurell
Journal:  J Natl Cancer Inst       Date:  2008-12-30       Impact factor: 13.506

7.  Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.

Authors:  Naohisa Yoshida; Toyoshi Hosokawa; Takeshi Ishikawa; Nobuaki Yagi; Satoshi Kokura; Yuji Naito; Masayoshi Nakanishi; Yukihito Kokuba; Eigo Otsuji; Haruo Kuroboshi; Masafumi Taniwaki; Tetsuya Taguchi; Hajime Hosoi; Terukazu Nakamura; Tsuneharu Miki
Journal:  J Oncol       Date:  2013-11-07       Impact factor: 4.375

8.  Effect of ECRG2 in combination with cisplatin on the proliferation and apoptosis of EC9706 cells.

Authors:  Hai-Yan Song; Xiao-Hui Deng; Xin-Fang Hou; Guo-Yan Yuan; Zhen-Dong Zhu; Ming-Xin Ren
Journal:  Exp Ther Med       Date:  2014-09-17       Impact factor: 2.447

9.  Mesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.

Authors:  Nils H Nicolay; Ramon Lopez Perez; Alexander Rühle; Thuy Trinh; Sonevisay Sisombath; Klaus-Josef Weber; Anthony D Ho; Jürgen Debus; Rainer Saffrich; Peter E Huber
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

10.  Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death.

Authors:  Daniela Catanzaro; Edoardo Gaude; Genny Orso; Carla Giordano; Giulia Guzzo; Andrea Rasola; Eugenio Ragazzi; Laura Caparrotta; Christian Frezza; Monica Montopoli
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.